Dr Michelle Parry

Map

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Weickhardt, A., Williams, D., Lee, C., Chionh, F., Simes, R., Murone, C., Byth Wilson, K., Parry, M., Asadi, K., Scott, A., et al (2015). Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer. British Journal of Cancer, 113(1), 37-45. [More Information]
  • Tebbutt, N., Parry, M., Zannino, D., Strickland, A., van Hazel, G., Pavlakis, N., Ganju, V., Mellor, D., Dobrovic, A., Gebski, V. (2013). Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. British Journal of Cancer, 108(4), 771-774. [More Information]
  • Goldstein, D., Spry, N., Cummins, M., Brown, C., van Hazel, G., Carroll, S., Selva-Nayagam, S., Borg, M., Ackland, S., Wratten, C., Hruby, G., Horvath, L., Gebski, V., et al (2012). The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. British Journal of Cancer, 106(1), 61-69. [More Information]
  • Price, T., Hardingham, J., Lee, C., Townsend, A., Wrin, J., Chua, A., Shivasami, A., Parry, M., Weikhardt, A., Tebbutt, N., et al (2011). Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. Journal of Clinical Oncology, 29(19), 2675-2682. [More Information]
  • Tebbutt, N., Murphy, F., Zannino, D., Wilson, C., Parry, M., Abdi, E., Strickland, A., Lowenthal, R., Marx, G., Karapetis, C., Shannon, J., Simes, R., et al (2011). Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Annals of Oncology, 22(8), 1834-1838. [More Information]
  • Tebbutt, N., Wilson, K., Gebski, V., Cummins, M., Zannino, D., van Hazel, G., Robinson, B., Broad, A., Ganju, V., Ackland, S., Stockler, M., Simes, R., et al (2010). Capecitabine, Bevacizumab and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study. Journal of Clinical Oncology, 28(19), 3191-3198. [More Information]
  • Hu, H., O'Mullane, L., Parry, M., Campbell, C., Hosoda, Y., Poronnik, P., Dinudom, A., Cook, D. (2010). Negative regulation of Ca2+ influx during P2Y2 purinergic receptor activation is mediated by Gβγ-subunits. Cell Calcium, 47(1), 55-64. [More Information]
  • Tebbutt, N., Parry, M., Sourjina, T., Strickland, A., van Hazel, G., Ganju, V., Gibbs, D., Stockler, M., Gebski, V., Zalcberg, J. (2010). Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. British Journal of Cancer, 102(3), 475-481. [More Information]
  • Parry, M., O'Mullane, L., Barden, J., Cook, D., Poronnik, P. (2002). Antisense co-suppression of Galphaq & Galpha11 demonstrates that both isoforms mediate M3-receptor-activated Ca2+ signalling in intact epithelial cells. Pfluegers Archiv: European journal of physiology, 444(5), 644-653. [More Information]
  • Poronnik, P., Parry, M., O'Mullane, L., Cook, D. (2002). Use of adenoviruses to study isoform specificity of G-protein-receptor- coupled Ca2+ signaling in intact epithelial cells. Cell Biochemistry and Biophysics, 36(2-3), 221-233. [More Information]
  • Parry, M., O'Mullane, L., Barden, J., Cook, D., Poronnik, P. (2000). Purinergic responses in HT29 colonic epithelial cells are mediated by G protein ?-subunits. Cell Calcium, 27(5), 247-255. [More Information]
  • Parry, M., Poronnik, P., O'Mullane, L., Cook, D. (2000). Studying heterotrimeric g-protein-linked signal transduction using replication-deficient adenoviruses. Immunology and Cell Biology, 78(4), 375-386. [More Information]

2015

  • Weickhardt, A., Williams, D., Lee, C., Chionh, F., Simes, R., Murone, C., Byth Wilson, K., Parry, M., Asadi, K., Scott, A., et al (2015). Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer. British Journal of Cancer, 113(1), 37-45. [More Information]

2013

  • Tebbutt, N., Parry, M., Zannino, D., Strickland, A., van Hazel, G., Pavlakis, N., Ganju, V., Mellor, D., Dobrovic, A., Gebski, V. (2013). Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. British Journal of Cancer, 108(4), 771-774. [More Information]

2012

  • Goldstein, D., Spry, N., Cummins, M., Brown, C., van Hazel, G., Carroll, S., Selva-Nayagam, S., Borg, M., Ackland, S., Wratten, C., Hruby, G., Horvath, L., Gebski, V., et al (2012). The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. British Journal of Cancer, 106(1), 61-69. [More Information]

2011

  • Price, T., Hardingham, J., Lee, C., Townsend, A., Wrin, J., Chua, A., Shivasami, A., Parry, M., Weikhardt, A., Tebbutt, N., et al (2011). Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. Journal of Clinical Oncology, 29(19), 2675-2682. [More Information]
  • Tebbutt, N., Murphy, F., Zannino, D., Wilson, C., Parry, M., Abdi, E., Strickland, A., Lowenthal, R., Marx, G., Karapetis, C., Shannon, J., Simes, R., et al (2011). Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Annals of Oncology, 22(8), 1834-1838. [More Information]

2010

  • Tebbutt, N., Wilson, K., Gebski, V., Cummins, M., Zannino, D., van Hazel, G., Robinson, B., Broad, A., Ganju, V., Ackland, S., Stockler, M., Simes, R., et al (2010). Capecitabine, Bevacizumab and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study. Journal of Clinical Oncology, 28(19), 3191-3198. [More Information]
  • Hu, H., O'Mullane, L., Parry, M., Campbell, C., Hosoda, Y., Poronnik, P., Dinudom, A., Cook, D. (2010). Negative regulation of Ca2+ influx during P2Y2 purinergic receptor activation is mediated by Gβγ-subunits. Cell Calcium, 47(1), 55-64. [More Information]
  • Tebbutt, N., Parry, M., Sourjina, T., Strickland, A., van Hazel, G., Ganju, V., Gibbs, D., Stockler, M., Gebski, V., Zalcberg, J. (2010). Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. British Journal of Cancer, 102(3), 475-481. [More Information]

2002

  • Parry, M., O'Mullane, L., Barden, J., Cook, D., Poronnik, P. (2002). Antisense co-suppression of Galphaq & Galpha11 demonstrates that both isoforms mediate M3-receptor-activated Ca2+ signalling in intact epithelial cells. Pfluegers Archiv: European journal of physiology, 444(5), 644-653. [More Information]
  • Poronnik, P., Parry, M., O'Mullane, L., Cook, D. (2002). Use of adenoviruses to study isoform specificity of G-protein-receptor- coupled Ca2+ signaling in intact epithelial cells. Cell Biochemistry and Biophysics, 36(2-3), 221-233. [More Information]

2000

  • Parry, M., O'Mullane, L., Barden, J., Cook, D., Poronnik, P. (2000). Purinergic responses in HT29 colonic epithelial cells are mediated by G protein ?-subunits. Cell Calcium, 27(5), 247-255. [More Information]
  • Parry, M., Poronnik, P., O'Mullane, L., Cook, D. (2000). Studying heterotrimeric g-protein-linked signal transduction using replication-deficient adenoviruses. Immunology and Cell Biology, 78(4), 375-386. [More Information]

To update your profile click here. For support on your academic profile contact .